AnaptysBio Swings to Profit on Soaring Collaboration Revenue

TL;DR

**ANAB's Q3 profit surge and planned split could unlock value, but watch that cash burn and R&D spend closely.**

AI Summary

AnaptysBio, Inc. (ANAB) reported a significant financial turnaround for the three months ended September 30, 2025, achieving a net income of $15.113 million, a substantial improvement from a net loss of $32.851 million in the same period of 2024. This was primarily driven by a surge in collaboration revenue, which more than doubled to $76.320 million from $30.017 million year-over-year. For the nine months ended September 30, 2025, the company still posted a net loss of $62.846 million, though this was a considerable reduction from the $123.447 million loss in the prior year. Research and development expenses decreased to $31.407 million for the quarter from $42.212 million, contributing to improved operating income. A key strategic development is the announced plan to separate the business into two independent, publicly traded companies by year-end 2026: one focused on managing Jemperli milestones and royalties, and the other on developing autoimmune and inflammatory therapeutics like rosnilimab, ANB033, and ANB101. The company's cash and cash equivalents decreased to $109.833 million as of September 30, 2025, from $123.080 million at December 31, 2024, partly due to $65.242 million in common stock repurchases.

Why It Matters

This filing signals a pivotal strategic shift for AnaptysBio, with the planned separation into two companies potentially unlocking significant shareholder value by creating focused entities. Investors should note the strong collaboration revenue growth, which indicates successful monetization of their out-licensed assets like Jemperli, providing a more stable revenue stream. The reduction in R&D expenses, while positive for the bottom line, will need careful monitoring to ensure it doesn't impede the progress of their core pipeline assets like rosnilimab, especially as they aim to launch a new biotech company with adequate capital. This move could also intensify competition in the autoimmune and inflammatory disease space, impacting other players.

Risk Assessment

Risk Level: medium — The company reported a total stockholders' deficit of $(29,416) thousand as of September 30, 2025, compared to equity of $70,868 thousand at December 31, 2024, indicating a deteriorating financial position despite the quarterly profit. Furthermore, net cash used in operating activities increased to $(78,300) thousand for the nine months ended September 30, 2025, from $(68,665) thousand in the prior year, highlighting ongoing operational cash burn.

Analyst Insight

Investors should closely monitor the progress of the announced business separation, as its successful execution and the capitalization of the new biotech entity will be critical. Given the significant stock repurchases of $65.242 million and the shift to a stockholders' deficit, investors should evaluate the company's capital allocation strategy and its ability to fund future operations and pipeline development without further dilution or debt.

Financial Highlights

debt To Equity

N/A

revenue

$76.320M

operating Margin

N/A

total Assets

$353.098M

total Debt

N/A

net Income

$15.113M

eps

$0.54

gross Margin

N/A

cash Position

$109.833M

revenue Growth

+154.3%

Revenue Breakdown

Key Numbers

• $15.113M — Net income for Q3 2025 (Significant improvement from a net loss of $32.851M in Q3 2024)
• $76.320M — Collaboration revenue for Q3 2025 (More than doubled from $30.017M in Q3 2024)
• $62.846M — Net loss for nine months ended Sept 30, 2025 (Reduced from $123.447M in the prior year period)
• $109.833M — Cash and cash equivalents as of Sept 30, 2025 (Decreased from $123.080M at Dec 31, 2024)
• $65.242M — Repurchases and retirements of common stock for nine months ended Sept 30, 2025 (Significant use of cash in financing activities)
• $(29,416)K — Total stockholders' deficit as of Sept 30, 2025 (Shift from $70,868K total stockholders' equity at Dec 31, 2024)
• $78.300M — Net cash used in operating activities for nine months ended Sept 30, 2025 (Increased from $68.665M in the prior year period)

Key Players & Entities

• ANAPTYSBIO, INC. (company) — registrant
• GSK (company) — collaborative partner for Jemperli
• Vanda Pharmaceuticals Inc. (company) — collaborative partner for imsidolimab
• Jemperli (dostarlimab-gxly) (drug) — out-licensed therapeutic antibody
• rosnilimab (drug) — lead program in Phase 2b for rheumatoid arthritis and Phase 2 for ulcerative colitis
• ANB033 (drug) — CD122 antagonist in Phase 1b for celiac disease
• ANB101 (drug) — BDCA2 modulator in Phase 1a trial
• Securities and Exchange Commission (regulator) — regulatory body

FAQ

Risk Factors

• Stockholders' Deficit [high — financial]: The company has a total stockholders' deficit of $29.416 million as of September 30, 2025, a significant shift from a positive equity of $70.868 million at December 31, 2024. This is largely due to common stock repurchases totaling $65.242 million.
• Cash Burn from Operations [medium — financial]: Net cash used in operating activities increased to $78.300 million for the nine months ended September 30, 2025, from $68.665 million in the prior year. This indicates a continued reliance on cash reserves to fund operations.
• Dependence on Collaboration Revenue [medium — operational]: While collaboration revenue surged by 154.3% to $76.320 million in Q3 2025, the company's profitability remains heavily tied to these partnerships. Any disruption or slowdown in these collaborations could significantly impact financial performance.
• Business Separation Uncertainty [medium — operational]: The planned separation into two independent companies by year-end 2026 introduces execution risk. The success of this complex restructuring, including regulatory approvals and market reception of the new entities, is not guaranteed.
• Decreasing Cash and Investments [medium — financial]: Cash and cash equivalents decreased to $109.833 million from $123.080 million, and short-term investments decreased from $262.293 million to $139.123 million. This reduction in liquid assets, partly due to stock repurchases, could limit future strategic flexibility.
• Product Development and Approval Risk [high — regulatory]: The company's future success hinges on the development and regulatory approval of its pipeline therapeutics, including rosnilimab, ANB033, and ANB101. Delays or failures in clinical trials or regulatory submissions pose significant risks.
• Competition in Therapeutic Areas [medium — market]: AnaptysBio operates in highly competitive markets for autoimmune and inflammatory diseases. The presence of established players and emerging therapies could impact market share and pricing power for its pipeline candidates.
• Liability Related to Future Royalties [high — financial]: The company carries a significant liability related to the sale of future royalties, amounting to $331.844 million as of September 30, 2025. This liability also incurs substantial non-cash interest expense, impacting net income.

Industry Context

AnaptysBio operates in the highly competitive biotechnology sector, focusing on developing therapeutics for autoimmune and inflammatory diseases. The industry is characterized by long development cycles, significant R&D investment, and reliance on strategic partnerships and potential acquisitions for growth and market access. Key trends include advancements in biologics, personalized medicine, and the increasing importance of collaborations for smaller biotechs to fund pipeline development.

Regulatory Implications

The company faces significant regulatory hurdles inherent in drug development. Successful progression of its pipeline candidates, such as rosnilimab, through clinical trials and subsequent FDA approval is critical. Any delays, adverse trial results, or regulatory rejections could severely impact the company's future prospects and the value of its assets.

What Investors Should Do

1. Monitor the execution of the business separation plan.
2. Analyze the sustainability of collaboration revenue.
3. Evaluate the cash burn rate and runway.
4. Assess the clinical and regulatory progress of key pipeline assets.
5. Consider the implications of the stockholders' deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net income of $15.113 million, a significant turnaround from a net loss in the prior year, driven by collaboration revenue.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $32.851 million, highlighting the substantial year-over-year improvement in the current period.
• 2026-12-31: Planned Business Separation — AnaptysBio plans to split into two independent public companies, one focused on Jemperli and the other on autoimmune/inflammatory therapeutics, a major strategic shift.
• 2025-12-31: Projected Year-End 2025 — The company aims to complete its business separation by this date, a critical milestone for its future structure and strategy.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents stood at $123.080 million, and total stockholders' equity was $70.868 million.

Glossary

Collaboration Revenue

Revenue generated from agreements with other companies, often involving milestone payments, research funding, or royalties from partnered products. (A primary driver of AnaptysBio's recent financial turnaround, more than doubling in Q3 2025.)

Stockholders' Deficit

A situation where a company's total liabilities exceed its total assets, resulting in negative equity for shareholders. (AnaptysBio reported a stockholders' deficit of $29.416 million as of September 30, 2025, indicating a significant negative net worth.)

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (AnaptysBio has an accumulated deficit of $822.173 million as of September 30, 2025, reflecting its history of operating losses.)

Common Stock Repurchases

When a company buys back its own shares from the open market, reducing the number of outstanding shares. (AnaptysBio used $65.242 million for common stock repurchases in the nine months ended September 30, 2025, contributing to the decrease in cash and the stockholders' deficit.)

Liability related to sale of future royalties

A financial obligation representing the value of future royalty payments that have been sold or securitized. (AnaptysBio has a substantial liability of $331.844 million related to this, which also carries significant non-cash interest expense.)

Rosnilimab

A therapeutic candidate developed by AnaptysBio, likely targeting autoimmune or inflammatory conditions. (It is one of the key assets that will be part of the new company formed after the business separation.)

Operating lease right-of-use assets

An asset recognized under accounting standards for leases, representing the right to use an asset for a specified period. (AnaptysBio has $12.994 million in these assets as of September 30, 2025.)

Comprehensive Income (Loss)

Includes net income or loss plus other gains and losses that are not included in net income, such as unrealized gains or losses on investments. (AnaptysBio reported comprehensive income of $15.166 million for Q3 2025, slightly higher than its net income due to unrealized gains on securities.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, AnaptysBio has demonstrated a significant financial recovery, turning a net loss of $32.851 million into a net income of $15.113 million. This turnaround was primarily fueled by a substantial increase in collaboration revenue, which more than doubled to $76.320 million. Research and development expenses also saw a reduction, contributing to improved operating results. However, the company's cash position has decreased, and it now faces the strategic challenge and associated risks of separating into two distinct entities.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value ANAB The Nasdaq Stock Market

Filing Documents

• anab-20250930.htm (10-Q) — 1483KB
• anab-9302025x10qxexx311.htm (EX-31.1) — 8KB
• anab-9302025x10qxexx312.htm (EX-31.2) — 8KB
• anab-9302025x10qxexx321.htm (EX-32.1) — 5KB
• anab-9302025x10qxexx322.htm (EX-32.2) — 5KB
• anab-20250930_g1.jpg (GRAPHIC) — 89KB
• 0001370053-25-000089.txt ( ) — 7952KB
• anab-20250930.xsd (EX-101.SCH) — 61KB
• anab-20250930_cal.xml (EX-101.CAL) — 55KB
• anab-20250930_def.xml (EX-101.DEF) — 251KB
• anab-20250930_lab.xml (EX-101.LAB) — 676KB
• anab-20250930_pre.xml (EX-101.PRE) — 465KB
• anab-20250930_htm.xml (XML) — 1155KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Consolidated Financial Statements (unaudited) 1 Consolidated Balance Sheets as of September 3 0 , 2025 and December 31, 2024 1 Consolidated Statements of Operations and Comprehensive Income ( Loss ) for the Three and Nine Months Ended September 3 0 , 2025 and 2024 2 Consolidated Statements of Stockholders' Equity (Deficit) for the Three and Nine Months Ended September 3 0 , 2025 3 Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 4 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Notes to the Unaudited Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 71 Item 3. Defaults Upon Senior Securities 72 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 73 Exhibit Index 73

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Consolidated Financial Statements (unaudited)

Item 1. Consolidated Financial Statements (unaudited) AnaptysBio, Inc. Consolidated Balance Sheets (in thousands, except par value data) (unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 109,833 $ 123,080 Receivables from collaborative partners 75,685 40,765 Short-term investments 139,123 262,293 Prepaid expenses and other current assets 6,009 5,738 Total current assets 330,650 431,876 Property and equipment, net 1,500 1,849 Operating lease right-of-use assets 12,994 14,383 Long-term investments 7,698 35,470 Other long-term assets 256 256 Total assets $ 353,098 $ 483,834 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 2,893 $ 4,002 Accrued expenses 33,171 39,501 Current portion of operating lease liability 2,040 1,925 Total current liabilities 38,104 45,428 Liability related to sale of future royalties 331,844 353,426 Operating lease liability, net of current portion 12,566 14,112 Stockholders' (deficit) equity: Preferred stock, $ 0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.001 par value, 500,000 shares authorized, 27,575 shares and 30,473 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 28 30 Additional paid in capital 792,682 829,860 Accumulated other comprehensive gain 47 305 Accumulated deficit ( 822,173 ) ( 759,327 ) Total stockholders' (deficit) equity ( 29,416 ) 70,868 Total liabilities and stockholders' (deficit) equity $ 353,098 $ 483,834 See accompanying notes to unaudited consolidated financial statements. 1 AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands, except per share data) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Collaboration revenue $ 76,320 $ 30

View Full Filing

View this 10-Q filing on SEC EDGAR